POWERFUL, DURABLE EFFICACY

VIrologIcally supPressed patIents

TANGO

TANGO Study Design

TANGO Baseline Characteristics1,2

This table  shows the baseline  characteristics  (including  age, sex, race, ethnicity,  CD4+ T-cell  count  and duration of prior ART) were  similar across both treatment  arms.

Adapted from van Wyk et al, 20201,2

POWERFUL, DURABLE EFFICACY MAINTAINED OUT TO 96 weeks IN PATIENTS SWITCHING FROM TAF-CONTAINING REGIMENS

In the TANGO study, DOVATO was non-inferior in maintaining virologic suppression vs a TAF-based regimen at week 48 (primary end-point), with no virologic failure or emergent resistance reported with DOVATO.

Non-inferiority Maintained With No Increased Risk of Virological Failure vs TAF-Containing Regimens2

This bar graph shows the virological outcomes at 2 years . DOVATO  maintained non-inferiority with no increas ed ris k of virological failure vs TAF-containing regimens.
This  graph s hows  the adjus ted treatm ent difference inproportionof patients with HIV-1 RNA greater than or equal to 50 copies/mL (based on a 4% non-inferiority margin), which favours DOVATO.

Adapted from van Wyk et al, 2020¹

References:

  1. van Wyk J, Ajana F, BisshopF, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Slides O441.
  2. van Wyk J, Ajana F, BisshopF, et al. Efficacy and safety of switching to dolutegravir/lami vudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920-1929. doi:10.1093/cid/ciz1243

PM-GB-DLL-WCNT-210004 I April 2021